Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia

NCT01853228 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT01853228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01853228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
October 22, 2013
Completion date
August 28, 2017
Enrollment
17 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia